{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,21]],"date-time":"2026-04-21T18:11:51Z","timestamp":1776795111808,"version":"3.51.2"},"reference-count":123,"publisher":"MDPI AG","issue":"2","license":[{"start":{"date-parts":[[2018,5,11]],"date-time":"2018-05-11T00:00:00Z","timestamp":1525996800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100008530","name":"European Regional Development Fund","doi-asserted-by":"publisher","award":["UID\/Multi\/04423\/2013, NORTE-01-0145-FEDER-000035"],"award-info":[{"award-number":["UID\/Multi\/04423\/2013, NORTE-01-0145-FEDER-000035"]}],"id":[{"id":"10.13039\/501100008530","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pharmaceuticals"],"abstract":"<jats:p>Neurodegenerative diseases are increasing in number, given that the general global population is becoming older. They manifest themselves through mechanisms that are not fully understood, in many cases, and impair memory, cognition and movement. Currently, no neurodegenerative disease is curable, and the treatments available only manage the symptoms or halt the progression of the disease. Therefore, there is an urgent need for new treatments for this kind of disease, since the World Health Organization has predicted that neurodegenerative diseases affecting motor function will become the second-most prevalent cause of death in the next 20 years. New therapies can come from three main sources: synthesis, natural products, and existing drugs. This last source is known as drug repurposing, which is the most advantageous, since the drug\u2019s pharmacokinetic and pharmacodynamic profiles are already established, and the investment put into this strategy is not as significant as for the classic development of new drugs. There have been several studies on the potential of old drugs for the most relevant neurodegenerative diseases, including Alzheimer\u2019s disease, Parkinson\u2019s disease, Huntington\u2019s disease, Multiple Sclerosis and Amyotrophic Lateral Sclerosis.<\/jats:p>","DOI":"10.3390\/ph11020044","type":"journal-article","created":{"date-parts":[[2018,5,11]],"date-time":"2018-05-11T03:42:48Z","timestamp":1526010168000},"page":"44","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":300,"title":["Old Drugs as New Treatments for Neurodegenerative Diseases"],"prefix":"10.3390","volume":"11","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4201-2774","authenticated-orcid":false,"given":"Fernando","family":"Dur\u00e3es","sequence":"first","affiliation":[{"name":"Laboratory of Organic and Pharmaceutical Chemistry, Department of Chemical Sciences, Faculty of Pharmacy, University of Porto, Rua Jorge Viterbo Ferreira, 228, 4050-313 Porto, Portugal"},{"name":"CIIMAR, Interdisciplinary Center of Marine and Environmental Research, University of Porto, Terminal de Cruzeiros do Porto de Leix\u00f5es, Avenida General Norton de Matos P, 4450-208 Matosinhos, Portugal"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4676-1409","authenticated-orcid":false,"given":"Madalena","family":"Pinto","sequence":"additional","affiliation":[{"name":"Laboratory of Organic and Pharmaceutical Chemistry, Department of Chemical Sciences, Faculty of Pharmacy, University of Porto, Rua Jorge Viterbo Ferreira, 228, 4050-313 Porto, Portugal"},{"name":"CIIMAR, Interdisciplinary Center of Marine and Environmental Research, University of Porto, Terminal de Cruzeiros do Porto de Leix\u00f5es, Avenida General Norton de Matos P, 4450-208 Matosinhos, Portugal"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5397-4672","authenticated-orcid":false,"given":"Em\u00edlia","family":"Sousa","sequence":"additional","affiliation":[{"name":"Laboratory of Organic and Pharmaceutical Chemistry, Department of Chemical Sciences, Faculty of Pharmacy, University of Porto, Rua Jorge Viterbo Ferreira, 228, 4050-313 Porto, Portugal"},{"name":"CIIMAR, Interdisciplinary Center of Marine and Environmental Research, University of Porto, Terminal de Cruzeiros do Porto de Leix\u00f5es, Avenida General Norton de Matos P, 4450-208 Matosinhos, Portugal"}]}],"member":"1968","published-online":{"date-parts":[[2018,5,11]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1038\/nrd1468","article-title":"Drug repositioning: Identifying and developing new uses for existing drugs","volume":"3","author":"Ashburn","year":"2004","journal-title":"Nat. Rev. Drug Discov."},{"key":"ref_2","first-page":"385","article-title":"Chapter 23\u2014The future of drug repositioning: Old drugs, new opportunities","volume":"Volume 46","author":"Macor","year":"2011","journal-title":"Annual Reports in Medicinal Chemistry"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1002\/wps.20481","article-title":"The promise and challenges of drug repurposing in psychiatry","volume":"17","author":"Fava","year":"2018","journal-title":"World Psychiatry"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1146\/annurev.med.53.082901.104043","article-title":"Thalidomide: Emerging role in cancer medicine","volume":"53","author":"Richardson","year":"2002","journal-title":"Annu. Rev. Med."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/j.phrs.2017.07.013","article-title":"Drug repurposing in cancer","volume":"124","author":"Sleire","year":"2017","journal-title":"Pharmacol. Res."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1016\/j.drudis.2018.01.018","article-title":"A bibliometric review of drug repurposing","volume":"23","author":"Baker","year":"2018","journal-title":"Drug Discov. Today"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1111\/j.1748-1716.1992.tb09370.x","article-title":"Neuronal plasticity and ageing processes in the frame of the \u2018red queen theory\u2019","volume":"145","author":"Agnati","year":"1992","journal-title":"Acta Physiol. Scand."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1111\/j.1749-6632.1992.tb27451.x","article-title":"Brain aging and neuronal plasticity","volume":"673","author":"Agnati","year":"1992","journal-title":"Ann. N. Y. Acad. Sci."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1242\/dmm.030205","article-title":"Neurodegenerative disease: Models, mechanisms, and a new hope","volume":"10","author":"Gitler","year":"2017","journal-title":"Dis. Models Mech."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1038\/nj7526-299a","article-title":"Neurodegenerative disease: Brain windfall","volume":"515","author":"Gammon","year":"2014","journal-title":"Nature"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1159\/000345791","article-title":"A review: Treatment of alzheimer\u2019s disease discovered in repurposed agents","volume":"35","author":"Appleby","year":"2013","journal-title":"Dement. Geriatr. Cogn. Disord."},{"key":"ref_12","first-page":"6378137","article-title":"Drug repurposing is a new opportunity for developing drugs against neuropsychiatric disorders","volume":"2016","author":"Lee","year":"2016","journal-title":"Schizophr. Res. Treat."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1080\/13543784.2017.1302426","article-title":"Drugs in clinical development for the treatment of amyotrophic lateral sclerosis","volume":"26","author":"Martinez","year":"2017","journal-title":"Expert Opin. Investig. Drugs"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/j.pharep.2014.09.004","article-title":"A review on alzheimer\u2019s disease pathophysiology and its management: An update","volume":"67","author":"Kumar","year":"2015","journal-title":"Pharmacol. Rep."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1016\/S0140-6736(15)01124-1","article-title":"Alzheimer\u2019s disease","volume":"388","author":"Scheltens","year":"2016","journal-title":"Lancet"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1038\/nrneurol.2017.111","article-title":"A systemic view of alzheimer disease\u2014Insights from amyloid-beta metabolism beyond the brain","volume":"13","author":"Wang","year":"2017","journal-title":"Nat. Rev. Neurol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"FSO73","DOI":"10.4155\/fso.15.73","article-title":"The case of galantamine: Repurposing and late blooming of a cholinergic drug","volume":"1","author":"Mucke","year":"2015","journal-title":"Future Sci. OA"},{"key":"ref_18","first-page":"157","article-title":"Chapter 4\u2014Galanthamine from galanthus and other amaryllidaceae\u2014Chemistry and biology based on traditional use","volume":"Volume 68","author":"Cordell","year":"2010","journal-title":"The Alkaloids: Chemistry and Biology"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"1295","DOI":"10.3233\/JAD-160840","article-title":"Do cancer drugs counteract neurodegeneration? Repurposing for alzheimer\u2019s disease","volume":"55","author":"Monacelli","year":"2017","journal-title":"J. Alzheimers Dis."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1016\/B978-0-444-52138-5.00017-7","article-title":"Chapter 17\u2014Chemotherapy with cytotoxic and cytostatic agents in brain cancer","volume":"Volume 104","author":"Aminoff","year":"2012","journal-title":"Handbook of Clinical Neurology"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1186\/1741-7015-11-81","article-title":"Striking reduction of amyloid plaque burden in an alzheimer\u2019s mouse model after chronic administration of carmustine","volume":"11","author":"Hayes","year":"2013","journal-title":"BMC Med."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"311","DOI":"10.2147\/NDT.S61309","article-title":"The emerging role of bexarotene in the treatment of alzheimer\u2019s disease: Current evidence","volume":"11","author":"Tousi","year":"2015","journal-title":"Neuropsychiatr. Dis. Treat."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"1206","DOI":"10.1248\/bpb.b12-00314","article-title":"Tamibarotene: A candidate retinoid drug for alzheimer\u2019s disease","volume":"35","author":"Fukasawa","year":"2012","journal-title":"Biol. Pharm. Bull."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"12444","DOI":"10.1073\/pnas.1534745100","article-title":"Gleevec inhibits \u03b2-amyloid production but not notch cleavage","volume":"100","author":"Netzer","year":"2003","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1016\/j.phrs.2010.12.002","article-title":"The characterization of microtubule-stabilizing drugs as possible therapeutic agents for alzheimer\u2019s disease and related tauopathies","volume":"63","author":"Brunden","year":"2011","journal-title":"Pharmacol. Res."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1073\/pnas.0406361102","article-title":"Microtubule-binding drugs offset tau sequestration by stabilizing microtubules and reversing fast axonal transport deficits in a tauopathy model","volume":"102","author":"Zhang","year":"2005","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1016\/j.nbd.2007.08.019","article-title":"Thalidomide inhibition of perturbed vasculature and glial-derived tumor necrosis factor-alpha in an animal model of inflamed alzheimer\u2019s disease brain","volume":"29","author":"Ryu","year":"2008","journal-title":"Neurobiol. Dis."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1016\/j.nbd.2010.07.002","article-title":"Tetracycline and its analogues protect caenorhabditis elegans from beta amyloid-induced toxicity by targeting oligomers","volume":"40","author":"Diomede","year":"2010","journal-title":"Neurobiol. Dis."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"41647","DOI":"10.1074\/jbc.M111.274548","article-title":"Testing the therapeutic potential of doxycycline in a drosophila melanogaster model of alzheimer disease","volume":"286","author":"Costa","year":"2011","journal-title":"J. Biol. Chem."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1111\/j.1532-5415.2004.52109.x","article-title":"A randomized, controlled trial of doxycycline and rifampin for patients with alzheimer\u2019s disease","volume":"52","author":"Loeb","year":"2004","journal-title":"J. Am. Geriatr. Soc."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1002\/gps.3846","article-title":"A multicenter, blinded, randomized, factorial controlled trial of doxycycline and rifampin for treatment of alzheimer\u2019s disease: The darad trial","volume":"28","author":"Molloy","year":"2013","journal-title":"Int. J. Geriatr. Psychiatry"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"6839","DOI":"10.1074\/jbc.271.12.6839","article-title":"Inhibition of amyloid beta protein aggregation and neurotoxicity by rifampicin. Its possible function as a hydroxyl radical scavenger","volume":"271","author":"Tomiyama","year":"1996","journal-title":"J. Biol. Chem."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"1364","DOI":"10.1016\/0140-6736(93)92274-W","article-title":"Existence of senile plaques in the brains of elderly leprosy patients","volume":"342","author":"Kimura","year":"1993","journal-title":"Lancet"},{"key":"ref_34","first-page":"771","article-title":"Decreased beta-amyloid and increased abnormal tau deposition in the brain of aged patients with leprosy","volume":"145","author":"Chui","year":"1994","journal-title":"Am. J. Pathol."},{"key":"ref_35","first-page":"157","article-title":"Neuropathological analysis of dementia in a japanese leprosarium","volume":"6","author":"Goto","year":"1995","journal-title":"Dementia"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/S0022-510X(99)00057-X","article-title":"No effect of anti-leprosy drugs in the prevention of alzheimer\u2019s disease and beta-amyloid neurotoxicity","volume":"165","author":"Endoh","year":"1999","journal-title":"J. Neurol. Sci."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1177\/1756285610370069","article-title":"Antiviral agents in alzheimer\u2019s disease: Hope for the future?","volume":"3","author":"Wozniak","year":"2010","journal-title":"Ther. Adv. Neurol. Disord."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"6228","DOI":"10.1021\/bi0270384","article-title":"Amphotericin b binds to amyloid fibrils and delays their formation: A therapeutic mechanism?","volume":"42","author":"Hartsel","year":"2003","journal-title":"Biochemistry"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"2366","DOI":"10.1016\/j.bmc.2009.02.016","article-title":"Amphotericin b interactions with soluble oligomers of amyloid abeta1-42 peptide","volume":"17","author":"Smith","year":"2009","journal-title":"Bioorg. Med. Chem."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"423","DOI":"10.3233\/JAD-2009-1063","article-title":"Clioquinol decreases amyloid-beta burden and reduces working memory impairment in a transgenic mouse model of alzheimer\u2019s disease","volume":"17","author":"Grossi","year":"2009","journal-title":"J. Alzheimers Dis."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/0197-4580(94)00150-2","article-title":"Anticonvulsants attenuate amyloid beta-peptide neurotoxicity, Ca2+ deregulation, and cytoskeletal pathology","volume":"16","author":"Mark","year":"1995","journal-title":"Neurobiol. Aging"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1016\/j.neuroscience.2010.04.041","article-title":"Valproic acid enhances microglial phagocytosis of amyloid-beta(1\u201342)","volume":"169","author":"Smith","year":"2010","journal-title":"Neuroscience"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"2781","DOI":"10.1084\/jem.20081588","article-title":"Valproic acid inhibits abeta production, neuritic plaque formation, and behavioral deficits in alzheimer\u2019s disease mouse models","volume":"205","author":"Qing","year":"2008","journal-title":"J. Exp. Med."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1001\/archgenpsychiatry.2011.72","article-title":"Chronic divalproex sodium to attenuate agitation and clinical progression of alzheimer disease","volume":"68","author":"Tariot","year":"2011","journal-title":"Arch. Gen. Psychiatry"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"S64","DOI":"10.1038\/sj.jhh.1001442","article-title":"The renin-angiotensin system in the brain: Possible therapeutic implications for at(1)-receptor blockers","volume":"16","author":"Culman","year":"2002","journal-title":"J. Hum. Hypertens."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.pneurobio.2011.07.001","article-title":"Brain renin-angiotensin\u2014A new look at an old system","volume":"95","author":"Wright","year":"2011","journal-title":"Prog. Neurobiol."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"3393","DOI":"10.1172\/JCI31547","article-title":"Valsartan lowers brain \u03b2-amyloid protein levels and improves spatial learning in a mouse model of alzheimer disease","volume":"117","author":"Wang","year":"2007","journal-title":"J. Clin. Investig."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"b5465","DOI":"10.1136\/bmj.b5465","article-title":"Use of angiotensin receptor blockers and risk of dementia in a predominantly male population: Prospective cohort analysis","volume":"340","author":"Li","year":"2010","journal-title":"BMJ"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1089\/rej.2009.0944","article-title":"Protective effects of intranasal losartan in the app\/ps1 transgenic mouse model of alzheimer disease","volume":"13","author":"Danielyan","year":"2010","journal-title":"Rejuvenation Res."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1097\/MNM.0b013e32804c58aa","article-title":"Favourable effects of nilvadipine on cognitive function and regional cerebral blood flow on spect in hypertensive patients with mild cognitive impairment","volume":"28","author":"Hanyu","year":"2007","journal-title":"Nucl. Med. Commun."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"49","DOI":"10.3233\/JAD-2009-0925","article-title":"Identification of antihypertensive drugs which inhibit amyloid-beta protein oligomerization","volume":"16","author":"Zhao","year":"2009","journal-title":"J. Alzheimers Dis."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1016\/j.ejphar.2011.03.048","article-title":"Selective dihydropyiridine compounds facilitate the clearance of beta-amyloid across the blood-brain barrier","volume":"659","author":"Bachmeier","year":"2011","journal-title":"Eur. J. Pharmacol."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ijcard.2017.02.083","article-title":"Trimetazidine in conditions other than coronary disease, old drug, new tricks?","volume":"234","author":"Zou","year":"2017","journal-title":"Int. J. Cardiol."},{"key":"ref_54","first-page":"17","article-title":"Trimetazidine prevents oxidative changes induced in a rat model of sporadic type of alzheimer\u2019s disease","volume":"53","author":"Hassanzadeh","year":"2015","journal-title":"Acta Med. Iran."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/j.ejphar.2004.02.050","article-title":"The role of insulin and insulin-like growth factor i in the molecular and cellular mechanisms underlying the pathology of alzheimer\u2019s disease","volume":"490","author":"Carro","year":"2004","journal-title":"Eur. J. Pharmacol."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/j.ejphar.2004.02.048","article-title":"Modulation of memory by insulin and glucose: Neuropsychological observations in alzheimer\u2019s disease","volume":"490","author":"Watson","year":"2004","journal-title":"Eur. J. Pharmacol."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/j.ejphar.2004.02.045","article-title":"Insulin and the insulin receptor in experimental models of learning and memory","volume":"490","author":"Zhao","year":"2004","journal-title":"Eur. J. Pharmacol."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1002\/jnr.10611","article-title":"Glucagon-like peptide-1 decreases endogenous amyloid-beta peptide (abeta) levels and protects hippocampal neurons from death induced by abeta and iron","volume":"72","author":"Perry","year":"2003","journal-title":"J. Neurosci. Res."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1124\/jpet.300.3.958","article-title":"A novel neurotrophic property of glucagon-like peptide 1: A promoter of nerve growth factor-mediated differentiation in pc12 cells","volume":"300","author":"Perry","year":"2002","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"6587","DOI":"10.1523\/JNEUROSCI.0529-11.2011","article-title":"The diabetes drug liraglutide prevents degenerative processes in a mouse model of alzheimer\u2019s disease","volume":"31","author":"McClean","year":"2011","journal-title":"J. Neurosci."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"623","DOI":"10.3233\/JAD-130584","article-title":"The neuroprotection of liraglutide on alzheimer-like learning and memory impairment by modulating the hyperphosphorylation of tau and neurofilament proteins and insulin signaling pathways in mice","volume":"37","author":"Xiong","year":"2013","journal-title":"J. Alzheimers Dis."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/j.neuroscience.2017.09.045","article-title":"Acylated and unacylated ghrelin confer neuroprotection to mesencephalic neurons","volume":"365","author":"Wagner","year":"2017","journal-title":"Neuroscience"},{"key":"ref_63","doi-asserted-by":"crossref","unstructured":"Lucchi, C., Curia, G., Vinet, J., Gualtieri, F., Bresciani, E., Locatelli, V., Torsello, A., and Biagini, G. (2013). Protective but not anticonvulsant effects of ghrelin and jmv-1843 in the pilocarpine model of status epilepticus. PLoS ONE, 8.","DOI":"10.1371\/journal.pone.0072716"},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"2718","DOI":"10.1002\/jnr.22088","article-title":"Desacyl-ghrelin and synthetic gh-secretagogues modulate the production of inflammatory cytokines in mouse microglia cells stimulated by beta-amyloid fibrils","volume":"87","author":"Bulgarelli","year":"2009","journal-title":"J. Neurosci. Res."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"11622","DOI":"10.1523\/JNEUROSCI.3153-08.2008","article-title":"Retinoic acid attenuates \u03b2-amyloid deposition and rescues memory deficits in an alzheimer\u2019s disease transgenic mouse model","volume":"28","author":"Ding","year":"2008","journal-title":"J. Neurosci."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"1246","DOI":"10.1111\/j.1460-9568.2010.07426.x","article-title":"Retinoic acid receptor-alpha signalling antagonizes both intracellular and extracellular amyloid-beta production and prevents neuronal cell death caused by amyloid-beta","volume":"32","author":"Jarvis","year":"2010","journal-title":"Eur. J. Neurosci."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"302","DOI":"10.2174\/156720509788486581","article-title":"Towards retinoid therapy for alzheimer\u2019s disease","volume":"6","author":"Shudo","year":"2009","journal-title":"Curr. Alzheimer Res."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"1643","DOI":"10.1096\/fj.08-121392","article-title":"Up-regulation of the alpha-secretase adam10 by retinoic acid receptors and acitretin","volume":"23","author":"Tippmann","year":"2009","journal-title":"FASEB J."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"2458","DOI":"10.1016\/j.neurobiolaging.2014.05.016","article-title":"Zileuton restores memory impairments and reverses amyloid and tau pathology in aged ad mice","volume":"35","author":"Lauretti","year":"2014","journal-title":"Neurobiol. Aging"},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1016\/j.bbr.2013.05.017","article-title":"Phosphodiesterase-5 inhibitor sildenafil prevents neuroinflammation, lowers beta-amyloid levels and improves cognitive performance in app\/ps1 transgenic mice","volume":"250","author":"Zhang","year":"2013","journal-title":"Behav. Brain Res."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1016\/j.neuropharm.2012.06.052","article-title":"Tadalafil crosses the blood-brain barrier and reverses cognitive dysfunction in a mouse model of ad","volume":"64","author":"Ricobaraza","year":"2013","journal-title":"Neuropharmacology"},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"1768","DOI":"10.1093\/brain\/awx074","article-title":"Repurposed drugs targeting eif2\u03b1-p-mediated translational repression prevent neurodegeneration in mice","volume":"140","author":"Halliday","year":"2017","journal-title":"Brain"},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"5981","DOI":"10.1111\/febs.12335","article-title":"The hallmarks of parkinson\u2019s disease","volume":"280","author":"Antony","year":"2013","journal-title":"FEBS J."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"17013","DOI":"10.1038\/nrdp.2017.13","article-title":"Parkinson disease","volume":"3","author":"Poewe","year":"2017","journal-title":"Nat. Rev. Dis. Prim."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"503","DOI":"10.3233\/JPD-160867","article-title":"Nilotinib effects in parkinson\u2019s disease and dementia with lewy bodies","volume":"6","author":"Pagan","year":"2016","journal-title":"J. Parkinsons Dis."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"3315","DOI":"10.1093\/hmg\/ddt192","article-title":"Nilotinib reverses loss of dopamine neurons and improves motor behavior via autophagic degradation of \u03b1-synuclein in parkinson\u2019s disease models","volume":"22","author":"Hebron","year":"2013","journal-title":"Hum. Mol. Genet."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"41755","DOI":"10.1038\/srep41755","article-title":"Repurposing doxycycline for synucleinopathies: Remodelling of \u03b1-synuclein oligomers towards non-toxic parallel beta-sheet structured species","volume":"7","author":"Barbosa","year":"2017","journal-title":"Sci. Rep."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1177\/1756285609338501","article-title":"A review of the use of zonisamide in parkinson\u2019s disease","volume":"2","author":"Bermejo","year":"2009","journal-title":"Ther. Adv. Neurol. Disord."},{"key":"ref_79","doi-asserted-by":"crossref","unstructured":"Fox, S.H., Katzenschlager, R., Lim, S.Y., Barton, B., de Bie, R.M.A., Seppi, K., Coelho, M., and Sampaio, C. (2018). International parkinson and movement disorder society evidence-based medicine review: Update on treatments for the motor symptoms of parkinson\u2019s disease. Mov. Disord.","DOI":"10.1002\/mds.27372"},{"key":"ref_80","doi-asserted-by":"crossref","unstructured":"Riederer, P., and Muller, T. (2018). Monoamine oxidase-b inhibitors in the treatment of parkinson\u2019s disease: Clinical-pharmacological aspects. J. Neural. Transm., 1\u20137.","DOI":"10.1007\/s00702-017-1826-4"},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1097\/00001756-199307000-00030","article-title":"L-deprenyl increases gfap immunoreactivity selectively in activated astrocytes in rat brain","volume":"4","author":"Biagini","year":"1993","journal-title":"Neuroreport"},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/0197-0186(94)90047-7","article-title":"The concept of astrocyte-kinetic drug in the treatment of neurodegenerative diseases: Evidence for l-deprenyl-induced activation of reactive astrocytes","volume":"25","author":"Biagini","year":"1994","journal-title":"Neurochem. Int."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s40263-012-0017-y","article-title":"Methylphenidate: A treatment for parkinson\u2019s disease?","volume":"27","author":"Devos","year":"2013","journal-title":"CNS Drugs"},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1038\/nrneurol.2017.140","article-title":"Exenatide\u2014A drug for diabetes and parkinson disease?","volume":"13","author":"Jankovic","year":"2017","journal-title":"Nat. Rev. Neurol."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"451","DOI":"10.3233\/JPD-171192","article-title":"Is exenatide a treatment for parkinson\u2019s disease?","volume":"7","author":"Athauda","year":"2017","journal-title":"J. Parkinsons Dis."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"2730","DOI":"10.1172\/JCI68295","article-title":"Exenatide and the treatment of patients with parkinson\u2019s disease","volume":"123","author":"Dickson","year":"2013","journal-title":"J. Clin. Investig."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"e612","DOI":"10.1038\/cddis.2013.139","article-title":"Exenatide promotes cognitive enhancement and positive brain metabolic changes in ps1-ki mice but has no effects in 3xtg-ad animals","volume":"4","author":"Bomba","year":"2013","journal-title":"Cell Death Dis."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1126\/science.aaf3934","article-title":"\u03922-adrenoreceptor is a regulator of the \u03b1-synuclein gene driving risk of parkinson\u2019s disease","volume":"357","author":"Mittal","year":"2017","journal-title":"Science"},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"15005","DOI":"10.1038\/nrdp.2015.5","article-title":"Huntington disease","volume":"1","author":"Bates","year":"2015","journal-title":"Nat. Rev. Dis. Prim."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1186\/1750-1172-5-40","article-title":"Huntington\u2019s disease: A clinical review","volume":"5","author":"Roos","year":"2010","journal-title":"Orphanet J. Rare Dis."},{"key":"ref_91","first-page":"545","article-title":"Tetrabenazine in the treatment of huntington\u2019s disease","volume":"3","author":"Paleacu","year":"2007","journal-title":"Neuropsychiatr. Dis. Treat."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1111\/j.1600-0404.1982.tb03060.x","article-title":"Tiapride in the treatment of huntington\u2019s chorea","volume":"65","author":"Roos","year":"1982","journal-title":"Acta Neurol. Scand."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1212\/WNL.44.5.821","article-title":"Clozapine in huntington\u2019s chorea","volume":"44","author":"Bonuccelli","year":"1994","journal-title":"Neurology"},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1034\/j.1600-0404.2002.01197.x","article-title":"Olanzapine in huntington\u2019s disease","volume":"105","author":"Paleacu","year":"2002","journal-title":"Acta Neurol. Scand."},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1007\/s40265-016-0670-4","article-title":"Current pharmacological approaches to reduce chorea in huntington\u2019s disease","volume":"77","author":"Coppen","year":"2017","journal-title":"Drugs"},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1080\/10401230701844802","article-title":"Risperidone and the treatment of psychiatric, motor, and cognitive symptoms in huntington\u2019s disease","volume":"20","author":"Duff","year":"2008","journal-title":"Ann. Clin. Psychiatry"},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1176\/appi.psy.47.1.70","article-title":"Quetiapine in the treatment of behavioral disturbances in patients with huntington\u2019s disease","volume":"47","author":"Alpay","year":"2006","journal-title":"Psychosomatics"},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1007\/978-3-7091-0579-5_14","article-title":"The n-methyl-d-aspartate antagonist memantine retards progression of huntington\u2019s disease","volume":"68","author":"Beister","year":"2004","journal-title":"J. Neural Transm. Suppl."},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1016\/j.mehy.2010.09.003","article-title":"Targeting glutamate mediated excitotoxicity in huntington\u2019s disease: Neural progenitors and partial glutamate antagonist--memantine","volume":"76","author":"Anitha","year":"2011","journal-title":"Med. Hypotheses"},{"key":"ref_100","first-page":"175","article-title":"Multiple sclerosis review","volume":"37","author":"Goldenberg","year":"2012","journal-title":"P&T"},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1146\/annurev.neuro.30.051606.094313","article-title":"Multiple sclerosis: An immune or neurodegenerative disorder?","volume":"31","author":"Trapp","year":"2008","journal-title":"Annu. Rev. Neurosci."},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1080\/03602532.2017.1316285","article-title":"The importance of drug metabolites synthesis: The case-study of cardiotoxic anticancer drugs","volume":"49","author":"Hrynchak","year":"2017","journal-title":"Drug Metab. Rev."},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"2018","DOI":"10.1016\/S0140-6736(02)12023-X","article-title":"Mitoxantrone in progressive multiple sclerosis: A placebo-controlled, double-blind, randomised, multicentre trial","volume":"360","author":"Hartung","year":"2002","journal-title":"Lancet"},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1177\/1756285609344375","article-title":"Cyclophosphamide in multiple sclerosis: Scientific rationale, history and novel treatment paradigms","volume":"2","author":"Awad","year":"2009","journal-title":"Ther. Adv. Neurol. Disord."},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1097\/WNF.0b013e318204cd90","article-title":"Cladribine: Mode of action and implications for treatment of multiple sclerosis","volume":"34","author":"Leist","year":"2011","journal-title":"Clin. Neuropharmacol."},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"1627","DOI":"10.1080\/14656566.2017.1372747","article-title":"An update on cladribine for relapsing-remitting multiple sclerosis","volume":"18","author":"Holmoy","year":"2017","journal-title":"Expert Opin. Pharmacother."},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1093\/brain\/aws325","article-title":"Targeting asic1 in primary progressive multiple sclerosis: Evidence of neuroprotection with amiloride","volume":"136","author":"Arun","year":"2013","journal-title":"Brain"},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1212\/WNL.0b013e3181d7d651","article-title":"Ibudilast in relapsing-remitting multiple sclerosis: A neuroprotectant?","volume":"74","author":"Barkhof","year":"2010","journal-title":"Neurology"},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"1688","DOI":"10.1056\/NEJM200105313442207","article-title":"Amyotrophic lateral sclerosis","volume":"344","author":"Rowland","year":"2001","journal-title":"N. Engl. J. Med."},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1111\/j.1468-1331.2006.01575.x","article-title":"Riluzole and amyotrophic lateral sclerosis survival: A population-based study in southern italy","volume":"14","author":"Zoccolella","year":"2007","journal-title":"Eur. J. Neurol."},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1080\/14656566.2017.1319937","article-title":"Clinical efficacy of edaravone for the treatment of amyotrophic lateral sclerosis","volume":"18","author":"Sawada","year":"2017","journal-title":"Expert Opin. Pharmacother."},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1186\/s12974-016-0620-9","article-title":"Post-paralysis tyrosine kinase inhibition with masitinib abrogates neuroinflammation and slows disease progression in inherited amyotrophic lateral sclerosis","volume":"13","author":"Trias","year":"2016","journal-title":"J. Neuroinflamm."},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1097\/00132985-200507000-00010","article-title":"Tamoxifen, a cancer therapy, explored for als","volume":"5","author":"Goodman","year":"2005","journal-title":"Neurol. Today"},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1046\/j.1471-4159.2003.01670.x","article-title":"Protein kinase and protein phosphatase expression in amyotrophic lateral sclerosis spinal cord","volume":"85","author":"Hu","year":"2003","journal-title":"J. Neurochem."},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"15024","DOI":"10.1073\/pnas.1206362109","article-title":"Autophagy activators rescue and alleviate pathogenesis of a mouse model with proteinopathies of the tar DNA-binding protein 43","volume":"109","author":"Wang","year":"2012","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1358\/dnp.2010.23.8.1500435","article-title":"The rise and fall of dimebon","volume":"23","author":"Bezprozvanny","year":"2010","journal-title":"Drug News Perspect."},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"e332","DOI":"10.1038\/tp.2013.97","article-title":"Latrepirdine: Molecular mechanisms underlying potential therapeutic roles in alzheimer\u2019s and other neurodegenerative diseases","volume":"3","author":"Bharadwaj","year":"2013","journal-title":"Transl. Psychiatry"},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/S0140-6736(08)61074-0","article-title":"Effect of dimebon on cognition, activities of daily living, behaviour, and global function in patients with mild-to-moderate alzheimer\u2019s disease: A randomised, double-blind, placebo-controlled study","volume":"372","author":"Doody","year":"2008","journal-title":"Lancet"},{"key":"ref_119","first-page":"155","article-title":"Evidence for the efficacy of latrepirdine (dimebon) treatment for improvement of cognitive function: A meta-analysis","volume":"38","author":"Jordan","year":"2014","journal-title":"J. Alzheimers Dis."},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1212\/WNL.0b013e318228bf11","article-title":"A randomized, double-blind, placebo-controlled trial of simvastatin to treat alzheimer disease","volume":"77","author":"Sano","year":"2011","journal-title":"Neurology"},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"343","DOI":"10.2174\/1567205054367900","article-title":"Atorvastatin therapy lowers circulating cholesterol but not free radical activity in advance of identifiable clinical benefit in the treatment of mild-to-moderate ad","volume":"2","author":"Sparks","year":"2005","journal-title":"Curr. Alzheimer Res."},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/S0022-3956(02)00085-7","article-title":"Persistence of cognitive impairment in geriatric patients following antidepressant treatment: A randomized, double-blind clinical trial with nortriptyline and paroxetine","volume":"37","author":"Nebes","year":"2003","journal-title":"J. Psychiatr. Res."},{"key":"ref_123","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.1016\/S1474-4422(14)70222-4","article-title":"Efficacy and safety of ceftriaxone for amyotrophic lateral sclerosis: Results of a multi-stage, randomised, double-blind, placebo-controlled, phase 3 study","volume":"13","author":"Cudkowicz","year":"2014","journal-title":"Lancet"}],"container-title":["Pharmaceuticals"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1424-8247\/11\/2\/44\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T15:04:12Z","timestamp":1760195052000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1424-8247\/11\/2\/44"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,5,11]]},"references-count":123,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2018,6]]}},"alternative-id":["ph11020044"],"URL":"https:\/\/doi.org\/10.3390\/ph11020044","relation":{},"ISSN":["1424-8247"],"issn-type":[{"value":"1424-8247","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,5,11]]}}}